Metastatic Melanoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma 
Cancer Therapy Advisor
Immune checkpoint inhibitors targeting CLTA-4 and PD-1 are dramatically improving survival rates among patients with metastatic melanoma, but toxicity is a serious concern. Common immune-related adverse events (irAEs) include colitis, hepatitis, ...

 


New Immunotherapy Shows Response for Metastatic Melanoma, Study Says - Curetoday.com



Curetoday.com
 
New Immunotherapy Shows Response for Metastatic Melanoma, Study Says 
Curetoday.com
"This is one of the first studies to use gene-modified TILs in metastatic melanoma patients. Before this, there had been just a couple other studies treating just a handful of patients," said investigator Rodabe N. Amaria, M.D., Department of Melanoma ...

 


How the Gut Microbiome Is Affecting Immunotherapy Response - AJMC.com Managed Markets Network



How the Gut Microbiome Is Affecting Immunotherapy Response 
AJMC.com Managed Markets Network
Researchers examined the gut microbiome of patients with metastatic melanoma who were being treated with anti?PD-1 immunotherapy, and they determined that patients with a more diverse population of gut bacteria or an abundance of certain types of ...

 


Immunotherapy: Gut bacteria modulate responses to PD-1 blockade - Nature.com



Nature.com
 
Immunotherapy: Gut bacteria modulate responses to PD-1 blockade 
Nature.com
These conclusions are underscored by findings of the second study, from a group led by Jennifer Wargo, in which the oral and gut microbiomes of patients with metastatic melanoma were analysed. ?We found that patients who responded to anti-PD-1 therapy ...

and more » 


Gauging Exelixis's High Hopes for Cotellic - Market Realist



Gauging Exelixis's High Hopes for Cotellic 
Market Realist
In the IMspire150 trial (also known as Trilogy), Cotellic is being studied in combination with vemurafenib and atezolizumab for the treatment of first-line BRAF, mutant-positive, locally advanced metastatic melanoma. The Cotellic-atezolizumab ...

 


Immunotherapy Combination Sparks a Response in Melanoma Brain Metastases - Curetoday.com



Curetoday.com
 
Immunotherapy Combination Sparks a Response in Melanoma Brain Metastases 
Curetoday.com
The combination of the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) sparked a response in nearly half of asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain, according to the ...

 


Record run of hot days continues but there's a sting in the tail of the state's heatwave - The Mercury



The Mercury
 
Record run of hot days continues but there's a sting in the tail of the state's heatwave 
The Mercury
After complaining of a sore back, an ultrasound showed growths on his liver and he was diagnosed with advanced metastatic melanoma. He died just eight months later in November last year. Mrs Barton said melanoma blindsided her family and everyone ...

and more » 


Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be ... - Nasdaq



Bibeypost.com
 
Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be ... 
Nasdaq
"The new study findings presented at SITC indicate encouraging preliminary efficacy from patients in Cohort 2 with advanced metastatic melanoma disease, who were treated with our cryopreserved TIL product LN-144," said Maria Fardis, PhD, MBA, Iovance ...
Iovance's lead candidate shows positive effect in mid-stage melanoma study; shares ahead 7% premarket Seeking Alpha

all 8 news articles » 


Tuning the Microbiome Improves Melanoma Immunotherapy Response - Genetic Engineering & Biotechnology News (press release)



Genetic Engineering & Biotechnology News (press release)
 
Tuning the Microbiome Improves Melanoma Immunotherapy Response 
Genetic Engineering & Biotechnology News (press release)
Patients with metastatic melanoma treated with anti-PD1 checkpoint blockade have their disease controlled longer if they have a more diverse population of bacteria in the gut or an abundance of certain types of bacteria, according to the MD Anderson ...
Gut Microbes May Contribute to Immunotherapy Response GenomeWeb
Gut microbiome modulates response to anti?PD-1 immunotherapy in melanoma patients | Science Science

all 48 news articles » 


Melanoma Exomes Implicate Antigen-Related Gene Changes in Immunotherapy Resistance - GenomeWeb



Melanoma Exomes Implicate Antigen-Related Gene Changes in Immunotherapy Resistance 
GenomeWeb
The researchers used exome sequencing to track protein-coding profiles in tumor samples taken over time in 17 individuals with metastatic melanoma who were treated with immune checkpoint blockade drugs targeting CTLA4 or PD1. They found that nearly ...